nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.03.2008

Current diagnosis of acromegaly

verfasst von: Rocio A. Cordero, Ariel L. Barkan

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Acromegaly is a rare and chronic condition that is characterized by sustained unregulated hypersecretion of growth hormone (GH). More than 99% of the cases of acromegaly are due to a pathologic proliferation of pituitary somatotrophs presenting in the form of a pituitary adenoma. The excessive amounts of GH and its target hormone, insulin like growth factor-1 (IGF-1) cause metabolic changes and tissue enlargement that, collectively, lead to significant morbidity and a two to threefold increase in mortality. Thus, early diagnosis has proved to be crucial to improve survival and quality of life in this condition. The development of radioimmunoassay (RIA) in the 1960s provided clinicians with a biochemical tool to diagnose acromegaly. Many limitations were inherent to this methodology which necessitated the development of more sensitive tools, such as immunoradiometric (IRMA) or immunoluminometric (ILMA) assays for GH and IGF-1 measurements. These newer assays have not come without imperfections. The reference ranges to describe normalcy of the somatotropic axis and the biochemical criteria of “cure” of acromegaly are areas of great debate. Nevertheless, the current international consensus agrees that the diagnosis of acromegaly should be based on both clinical presentation and biochemical data.

Bengtsoon BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemilogy and long term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327–5.CrossRef

Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2(1):29–41. (Jun).PubMedCrossRef

Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41(1):95–102. (Jul).

Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest 1993;16(3):181–7. (Mar).PubMed

Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 1993;151(4):439–6. Oct.CrossRef

Melmed S. Acromegaly. N Engl J Med 1993;322(14):966–77. (Apr 5).CrossRef

Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996;81:2642–6.PubMedCrossRef

Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein α-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675–705.PubMedCrossRef

Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome: analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996;97:699–705.PubMedCrossRef

10.

Gadelha MR, Prezant TR, Une KN, Glick RP, Moskal SF 2nd, Vaisman M, et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab 1999;84:249–56.PubMedCrossRef

11.

Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev 1988;9(3):357–73. (Aug).PubMed

12.

Barkan AL, Stred SE, Reno K, Markovs M, Hopwood NJ, Kelch RP, et al. Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 1989;69(6):1225–33. (Dec).PubMed

13.

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102–52. (Feb).PubMedCrossRef

14.

Künzler A, Farmand M. Typical changes in the viscerocranium in acromegaly. J Craniomaxillofac Surg 1991;19(8):332–40.PubMed

15.

Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. Neuroendocrinology 2006;83(3–4):211–7.PubMedCrossRef

16.

Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf) 1998;49(1):101–6. (Jul).CrossRef

17.

Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, Bone F, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000;85(1):179–82. (Jan).PubMedCrossRef

18.

Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86(4):1551–7. (Apr).PubMedCrossRef

19.

Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15(5):555–73. (Oct).PubMedCrossRef

20.

Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986;250(3 Pt 1):E269–73. (Mar).PubMed

21.

Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992;74(5):1012–9. (May).PubMedCrossRef

22.

Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987;8(2):115–31. (May).PubMed

23.

Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994;121(7):478–83. (Oct 1).PubMed

24.

Layton MW, Fudman EJ, Barkan A, Braunstein EM, Fox IH. Acromegalic arthropathy. Characteristics and response to therapy. Arthritis Rheum 1988;31(8):1022–7. (Aug).PubMedCrossRef

25.

Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 1999;51(5):611–8. (Nov).CrossRef

26.

Jenkins PJ. Acromegaly and cancer. Horm Res 1999;62(Suppl 1):108–5.

27.

Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001;86(7):2929–34. (Jul).PubMedCrossRef

28.

Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 2002;87(4):1909. (Apr).PubMedCrossRef

29.

Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730–4. (Aug).PubMedCrossRef

30.

Duncan E, Wass JA. Investigation protocol: acromegaly and its investigation. Clin Endocrinol (Oxf) 1999;50(3):285–93. (Mar).CrossRef

31.

Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Clin Endocrinol Metab 1988;67(1):69–73. (Jul).CrossRef

32.

Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997;278(5337):419–24. (Oct 17).PubMedCrossRef

33.

Desailloud R, Crepin-Hemon S, Simovic-Corroyer B. Acromegaly in elderly people. Ann Endocrinol (Paris) 2005;66(6):540–4. (Dec).

34.

Glick AM, Roth J, Yalow RF, Berson SA. Immunoassay of human growth hormone in plasma. Nature 1963;199:784–7.PubMedCrossRef

35.

Ho PJ, Friberg RD, Barkan AL. Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab 1992;75(3):812–9.PubMedCrossRef

36.

Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 1994;78(6):1403–10.PubMedCrossRef

37.

Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, et al. Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand Suppl 1994;379:63–70.

38.

Baumann G, Shaw M, Amburn K, Jan T, Davila N, Mercado M, et al. Heterogeneity of circulating growth hormone. Nucl Med Biol 1994;21(3):369–79. (Apr).PubMedCrossRef

39.

Ebdrup L, Fisker S, Rensen HH, Ranke MB, Orskov H. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Horm Res 1994;51(Suppl 1):20–6.

40.

Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-1 assays limits the applicability of international consensus criteria for local practice. Clin Endocrinol (Oxf) 2007;67(1):65–70. (Jul).CrossRef

41.

Christy NP. Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. N Engl J Med 1992;326(4):266–7. (Jan 23).PubMedCrossRef

42.

Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 1993;78(2):205–15. (Feb).PubMed

43.

Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86(5):293–9. (May).PubMed

44.

Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85(2):526–9. (Feb).PubMedCrossRef

45.

Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808–16.PubMedCrossRef

46.

Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004;89(2):495–500. (Feb).PubMedCrossRef

47.

Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, et al. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 2005;90(3):1377–82. (Mar).PubMedCrossRef

48.

Costas ACF, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure. J Clin Endocrinol Metab 2002;87(7):3142–7.CrossRef

49.

Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Clin Endocrinol Metab 2004;89(2):658–1. (Feb).CrossRef

50.

Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WL, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002;87(8):3537–42.PubMedCrossRef

51.

Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355(24):2558–73. (Dec 14).PubMedCrossRef

52.

Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301(21):1138–42.PubMedCrossRef

53.

Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-i and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 1998;83:2554–61.PubMedCrossRef

54.

Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–26.PubMedCrossRef

55.

Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after Transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58(1):86–91.CrossRef

56.

Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13(4):185–92.PubMedCrossRef

57.

Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Scutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789–96.PubMedCrossRef

58.

Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996;134(3):352–6. (Mar).PubMed

59.

Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60(2):53–60.PubMedCrossRef

60.

Freda PU. Pitfalls in the biochemical assessment of acromegaly. Pituitary 2003;6(3):135–40.PubMedCrossRef

61.

Ho KK, O'Sullivan AJ, Wolthers T, Leung KC. Metabolic effects of estrogens: impact of the route of administration. Ann Endocrinol (Paris) 2003;64(2):170–7.

62.

Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001;54(2):183–8. (Feb).CrossRef

63.

Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153(6):737–40. (Dec).PubMedCrossRef

64.

Losa M, von Werder K. Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clin Endocrinol (Oxf) 1997;47(2):123–35. (Aug).CrossRef

65.

Vieira Neto L, Taboada GF, Corrêa LL, Polo J, Nascimento AF, Chimelli L, et al. Acromegaly secondary to growth hormone-releasing hormone secreted by an incidentally discovered pheochromocytoma. Endocr Pathol 2007;18(1):46–52. (Spring).PubMedCrossRef

66.

Sugihara H, Shibasaki T, Tatsuguchi A, Okajima F, Wakita S, Nakajima Y, et al. A non-acromegalic case of multiple endocrine neoplasia type 1 accompanied by a growth hormone-releasing hormone-producing pancreatic tumor. J Endocrinol Invest 2007;30(5):421–7. (May).PubMed

67.

Fainstein Day P, Frohman L, Garcia Rivello H, Reubi JC, Sevlever G, Glerean M, et al. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary 2007;10:311–19.PubMedCrossRef

68.

Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab 2006;91(12):4776–80. (Dec).PubMedCrossRef

69.

Bolanowski M, Kos-Kudła B, Rzeszutko M, Marciniak M, Zatońska K. Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease. Endokrynol Pol 2006;57(1):32–6. (Jan–Feb).PubMed

70.

Jansson JO, Svensson J, Bengtsson BA, Frohman LA, Ahlman H, Wängberg B, et al. Acromegaly and Cushing’s syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol 1998;48:243–50.CrossRef

71.

Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooy PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283–92.PubMedCrossRef

72.

Drange MR, Melmed S. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab 1998;83:3104–9.PubMedCrossRef

Titel: Current diagnosis of acromegaly
verfasst von: Rocio A. Cordero
Ariel L. Barkan
Publikationsdatum: 01.03.2008
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2008
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-007-9060-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Management of acromegaly: Is there a role for primary medical therapy?

Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune–Albright syndrome, familial acromegaly and genetic defects in sporadic tumors

Does acromegaly enhance mortality?

Medical therapy: Options and uses

Medical consequences of acromegaly: What are the effects of biochemical control?